Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM CRITERIA FOR THE CLINICAL USE OF PROPOSED REVISIONS TO THE CRITERIA SWG RATIONALE FOR PROPOSED CHANGE INTRAVENOUS IMMUNOGLOBULIN IN (A) Administrative) AUSTRALIA, SECOND EDITION (CRITERIA) (B) Progressive (C) Programmed Potassium channel antibody-associated Chapter 7 has not yet undergone a formal Condition Autoimmune encephalitis mediated by encephalopathy review, however, feedback from the public Name antibodies targeting cell-surface antigens consultation has requested this condition be (also includes some but not all patients developed to re-structure eligible patients currently eligible under Chapter 7 covered by several existing conditions in conditions: Limbic encephalitis — Chapter 7: nonparaneoplastic and Limbic Potassium channel antibody-associated encephalopathy all patients encephalitis paraneoplastic). – — and only trial patients with antibodies directed against extra-cellular neural antigens from Limbic encephalitis nonparaneoplastic — Limbic encephalitis paraneoplastic — as they will respond to Ig therapy. Chapter 7 requires significant review and restructuring including sub sensory neuropathy, paraneoplastic cerebellar degeneration, paraneoplastic limbic encephalitis with Ab to intracellular antigens. Specialty Neurology Neurology
Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM CRITERIA FOR THE CLINICAL USE OF INTRAVENOUS IMMUNOGLOBULIN IN AUSTRALIA, SECOND EDITION (CRITERIA) PROPOSED REVISIONS TO THE CRITERIA SWG RATIONALE FOR PROPOSED CHANGE (A) Administrative) (B) Progressive (C) Programmed Condition Name Potassium channel antibody-associated encephalopathy (also includes some but not all patients currently eligible under Chapter 7 conditions: Limbic encephalitis — nonparaneoplastic and Limbic encephalitis — paraneoplastic). Autoimmune encephalitis mediated by antibodies targeting cell-surface antigens Chapter 7 has not yet undergone a formal review, however, feedback from the public consultation has requested this condition be developed to re-structure eligible patients covered by several existing conditions in Chapter 7: Potassium channel antibody-associated encephalopathy – all patients and only patients with antibodies directed against extra-cellular neural antigens from Limbic encephalitis — nonparaneoplastic Limbic encephalitis — paraneoplastic as they will respond to Ig therapy. Chapter 7 requires significant review and restructuring including sub sensory neuropathy, paraneoplastic cerebellar degeneration, paraneoplastic limbic encephalitis with Ab to intracellular antigens. Specialty Neurology Neurology trial